Skip NavigationSkip to Content

Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins

  1. Author:
    Baleja, J. D.
    Cherry, J. J.
    Liu, Z. G.
    Gao, H.
    Nicklaus, M. C.
    Voigt, J. H.
    Chen, J. J.
    Androphy, E. J.
  2. Author Address

    Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA. Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA. NCI, Ctr Canc Res, Med Chem Lab, Frederick, MD 21702 USA.;Baleja, JD, Tufts Univ, Sch Med, Dept Biochem, 136 Harrison Ave, Boston, MA 02111 USA.;jim.baleja@tufts.edu jason.chen@umassmed.edu
    1. Year: 2006
    2. Date: Oct
  1. Journal: Antiviral Research
    1. 72
    2. 1
    3. Pages: 49-59
  2. Type of Article: Article
  3. ISSN: 0166-3542
  1. Abstract:

    Human papillomaviruses (HPV) cause cutaneous and genital warts. A subset of HPV types is associated with a high-risk for progression to malignancy. The E6 protein from the high-risk HPV types represents an attractive target for intervention because of its roles in viral propagation and cellular transformation. E6 functions in part by interaction with human cellular proteins, several of which possess a helical E6-binding motif. The role for each amino acid in this motif for binding E6 has been tested through structure determination and site-directed mutagenesis. These structural and molecular biological approaches defined the spatial geometry of functional groups necessary for binding to E6. This E6-binding information (the E6-binding pharmacophore) was transferred into a three-dimensional query format suitable for computational screening of large chemical databases. Compounds were identified and tested using in vitro and cell culture-based assays. Several compounds selectively inhibited E6 interaction with the E6-binding protein E6AP and interfered with the ability of E6 to promote p53 degradation. Such compounds provide leads for the development of new pharmacologic agents to treat papillomavirus infections and their associated cancers. (c) 2006 Elsevier B.V. All rights reserved.

    See More

External Sources

  1. DOI: 10.1016/j.antiviral.2006.03.014
  2. WOS: 000240708600006

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel